Journal of Pain review boost for GW Pharm

GW Pharmaceuticals, the developer of cannabis-based medicinal products, has released a puff piece about a favourable review of its Sativex product in a US medical journal.

GW Pharmaceuticals, the developer of cannabis-based medicinal products, has released a puff piece about a favourable review of its Sativex product in a US medical journal.

The "Journal of Pain", the official journal of the American Pain Society, has published the full results from a Phase IIb dose-ranging trial evaluating the efficacy and safety of Sativex in the treatment of pain in patients with advanced cancer, who experience inadequate pain relief (analgesia) during optimised chronic pain suppression therapy.

Subscribe to MoneyWeek

Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Get 6 issues free
https://cdn.mos.cms.futurecdn.net/flexiimages/mw70aro6gl1676370748.jpg

Sign up to Money Morning

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Sign up
MoneyWeek

MoneyWeek is written by a team of experienced and award-winning journalists, plus expert columnists. As well as daily digital news and features, MoneyWeek also publishes a weekly magazine, covering investing and personal finance. From share tips, pensions, gold to practical investment tips - we provide a round-up to help you make money and keep it.